CCL7 and CSF2 exhibited a significant increase in expression in group “a” vs TNBC, ER+ and HER2+ breast cancer samples, whereas CXCL8, ICAM1, CCL8, IGFBP3, CXCL1, CCL13, CCL2 and IL6 were elevated in group “a” relative to ER+ and HER2+ lesions (Supplemental Fig. 9E). Here, CCL13 is linked to breast carcinoma.